2023 2024 EduVark > Education Discussion > General Discussion


  #2  
June 27th, 2016, 03:41 PM
Super Moderator
 
Join Date: Mar 2012
Re: Oxycodone HCL BCS Class

Outline of Clinical Pharmacology and Biopharmaceutics Findings by Lehigh Valley Technologies, Inc. (LVT) presented this 505(b)(2) NDA for Oxycodone Hydrochloride Capsules, 5 mg for the administration of moderate to extreme torment where utilization of an opioid pain relieving is suitable. Support has been showcasing this item without an endorsed NDA.

Oxycodone is an opioid pain relieving that was initially combined in 1916. Single-fixing oxycodone

hydrochloride prompt discharge oral tablets are endorsed in the US in qualities running from 5 mg to 30 mg for administration of moderate to serious torment where the utilization of an opioid pain relieving is proper. Support at first planed to depend on the Agency's past discoveries of the wellbeing and adequacy of Roxicodone®

What are the proposed mechanism(s) of activity and restorative indication(s)?

Oxycodone is an immaculate agonist opioid whose guideline remedial activity is pain relieving. Oxycodone container is shown for the administration of moderate to extreme agony where the utilization of an opiod pain relieving is fitting.

What are the proposed dosage(s) and route(s) of organization?

Oxycodone cases are prompt discharge oral plan.



Quick Reply
Your Username: Click here to log in

Message:
Options



All times are GMT +5. The time now is 01:42 AM.


Powered by vBulletin® Version 3.8.11
Copyright ©2000 - 2024, vBulletin Solutions Inc.
Content Relevant URLs by vBSEO 3.6.0

1 2 3 4 5 6 7 8